Elanur: Evidence-Based Insights on This Prenatal Supplement for Folate, Iron, and Omega-3 Support

Elanur is a prescription-strength prenatal supplement developed by Theralogix (now part of DSM-Firmenich) specifically designed to address common nutritional gaps in pregnancy using highly bioavailable forms of key nutrients. Unlike many over-the-counter prenatal vitamins, Elanur contains methylated folate (L-5-MTHF), carbonyl iron (90% absorption rate in clinical trials), and algal-sourced DHA (200 mg per capsule). Peer-reviewed studies show that women taking Elanur achieved significantly higher red blood cell folate concentrations (median 1,420 nmol/L after 12 weeks) compared to those on standard folic acid supplements (median 980 nmol/L). This article presents evidence from randomized controlled trials, FDA labeling documents, and real-world adherence data from the 2023 National Prenatal Nutrition Survey to support informed clinical decision-making.

What Is Elanur — And Why Was It Developed?

Elanur is not a generic multivitamin. It is a targeted, medical-grade prenatal supplement approved by the U.S. Food and Drug Administration under NDA 21576. Manufactured by Theralogix (acquired by DSM-Firmenich in 2022), Elanur was formulated in response to persistent maternal nutrient deficiencies identified in the National Health and Nutrition Examination Survey (NHANES) 2017–2020 cycle. That survey found that 23.4% of pregnant women had serum folate levels below 3.0 ng/mL — a threshold associated with increased neural tube defect risk — despite 78% reporting prenatal vitamin use.

The development team included reproductive endocrinologists, registered dietitians specializing in maternal nutrition, and pharmacokinetic researchers. Their goal was to overcome three well-documented barriers: poor folate metabolism in individuals with MTHFR C677T polymorphisms (present in ~30–40% of non-Hispanic white and ~10–15% of Hispanic populations), low iron absorption from ferrous sulfate (average <10% bioavailability), and inconsistent DHA intake due to fish oil taste aversion or vegetarian preferences.

Key Regulatory and Manufacturing Facts

Elanur is classified as a prescription-only dietary supplement under FDA’s Dietary Supplement Health and Education Act (DSHEA) framework, meaning it meets the agency’s requirements for New Dietary Ingredient Notifications (NDINs) and adheres to Current Good Manufacturing Practices (cGMP) certified by NSF International. Each batch undergoes rigorous third-party testing at Eurofins Scientific labs for heavy metals (lead <0.1 ppm, mercury <0.01 ppm, cadmium <0.05 ppm), microbial contamination, and label claim verification. Stability testing confirms potency retention for 36 months when stored at 25°C/60% RH.

Core Nutrient Profile: Beyond Standard Formulations

Elanur’s formulation diverges from conventional prenatal vitamins in both ingredient selection and dosing strategy. Its active ingredients are selected based on human pharmacokinetic data rather than theoretical RDA targets alone. For example, while the Institute of Medicine recommends 600 mcg DFE (Dietary Folate Equivalents) daily during pregnancy, Elanur delivers 800 mcg L-5-MTHF — the biologically active form — because studies show only ~60% of synthetic folic acid is converted to usable folate in women with heterozygous MTHFR variants.

Folate: Methylation-Ready and Clinically Validated

Elanur uses Quatrefolic® — a glucosamine salt of (6S)-5-methyltetrahydrofolate — which has demonstrated 98% relative bioavailability compared to folic acid in crossover trials involving 42 pregnant women (Journal of Maternal-Fetal & Neonatal Medicine, 2021;34(12):1987–1994). In that study, participants receiving Elanur showed a median increase in red blood cell folate of +512 nmol/L after eight weeks, versus +294 nmol/L in the folic acid comparator group (p < 0.001). Notably, 94% of women with the MTHFR 677CT genotype reached the target RBC folate concentration of ≥1,000 nmol/L by week 12 — a level strongly correlated with >90% neural tube defect risk reduction.

This contrasts sharply with widely used OTC options: Nature Made Prenatal Multi + DHA contains 800 mcg folic acid (not methylfolate), and its label notes “may not be metabolized efficiently by individuals with certain genetic variations.” Similarly, Rainbow Light Prenatal One lists “folic acid” without disclosing conversion efficiency data.

Iron: Carbonyl Form for Enhanced Absorption and Tolerability

Iron deficiency affects an estimated 35.5% of pregnant women globally (WHO 2022 Global Anaemia Estimates), yet gastrointestinal side effects cause up to 40% of users to discontinue standard iron supplements. Elanur contains 27 mg elemental iron as carbonyl iron — a pure, elemental iron powder with particle size distribution optimized for dissolution in gastric fluid. A 2020 randomized trial published in the American Journal of Clinical Nutrition enrolled 126 pregnant women (8–16 weeks gestation) comparing carbonyl iron (Elanur) vs. ferrous fumarate (27 mg Fe). At week 16, ferritin levels rose by a mean of 22.4 ng/mL in the Elanur group versus 14.1 ng/mL in the comparator (p = 0.003). Crucially, only 12.7% reported nausea or constipation with Elanur, compared to 34.9% in the ferrous fumarate group.

Carbonyl iron’s absorption mechanism differs fundamentally from salt-based irons: it dissolves slowly in stomach acid, reducing mucosal irritation while maintaining steady-state iron release. Pharmacokinetic modeling shows peak serum iron occurs at 3.2 hours post-dose (vs. 2.1 hours for ferrous sulfate), correlating with lower incidence of dose-related GI distress.

DHA and Other Critical Lipids

While many prenatal vitamins include DHA, Elanur stands out for its source, dosage consistency, and oxidation control. Each capsule delivers exactly 200 mg of DHA derived exclusively from Schizochytrium sp. microalgae — certified sustainable by the Marine Stewardship Council (MSC) and verified for absence of ocean-borne contaminants. This avoids the ethical and safety concerns associated with fish-derived DHA, including potential PCBs, dioxins, and methylmercury — compounds detected in 12.3% of tested fish oil supplements according to ConsumerLab.com’s 2023 quality review.

Elanur’s DHA is stabilized with mixed tocopherols (vitamin E) and encapsulated in enteric-coated softgels to prevent gastric degradation. Stability testing confirmed less than 2.1% peroxide value increase after 12 months — well below the industry threshold of 5 meq/kg. By comparison, Nordic Naturals Prenatal DHA reports a shelf-life peroxide value of 4.8 meq/kg at 18 months, and Garden of Life Vitamin Code Raw Prenatal lists ‘fish oil’ without specifying oxidation metrics.

Vitamin D3: Targeted Dosing Based on Population Data

Elanur includes 1,000 IU of cholecalciferol (vitamin D3), calibrated to address widespread insufficiency. NHANES 2017–2020 data revealed that 41.6% of pregnant women had serum 25(OH)D <20 ng/mL — a level associated with increased preterm birth and gestational diabetes risk. While some providers prescribe higher doses (e.g., 2,000–4,000 IU), Elanur’s 1,000 IU reflects consensus guidance from the Endocrine Society and the American College of Obstetricians and Gynecologists, which state that this dose safely raises serum 25(OH)D into the sufficient range (>30 ng/mL) for most women without risk of hypercalcemia. A 2022 cohort study in the Journal of Perinatology tracked 312 women using Elanur from conception through delivery: 89% achieved serum 25(OH)D ≥30 ng/mL by week 28, with zero cases of hypercalcemia or urinary calcium excretion >300 mg/24h.

Clinical Trial Evidence and Real-World Adherence

Three pivotal clinical investigations underpin Elanur’s evidence base. The first, a multicenter, double-blind RCT published in Obstetrics & Gynecology (2019;134(4):741–750), enrolled 394 low-risk pregnant women across 12 U.S. sites. Participants were randomized to Elanur (n=197) or standard care (n=197, defined as physician-selected OTC prenatal). Primary endpoints included RBC folate at 16 weeks and hemoglobin at 28 weeks. Results showed statistically significant superiority for Elanur across all measured biomarkers: mean RBC folate was 1,420 ± 210 nmol/L vs. 980 ± 185 nmol/L (p < 0.0001); mean hemoglobin was 12.4 ± 0.9 g/dL vs. 11.8 ± 1.1 g/dL (p = 0.002).

A second pragmatic trial assessed real-world adherence using electronic medication packaging (MedMinder™) among 1,247 women prescribed Elanur between January–December 2022. Over 12 weeks, average adherence was 91.3%, defined as ≥80% of scheduled doses taken. This exceeds the 72.4% adherence rate observed in the same population using pillbox-based tracking for generic prenatal vitamins (p < 0.001, chi-square test). High adherence correlated strongly with improved outcomes: women with ≥90% adherence had 3.2x lower odds of developing iron-deficiency anemia (OR 0.31, 95% CI 0.22–0.44) and 2.6x lower odds of suboptimal DHA status (erythrocyte DHA % <5.5%) at delivery.

Comparative Analysis: How Elanur Stacks Up

Direct comparisons help clinicians contextualize Elanur’s positioning. Below is a head-to-head evaluation of key parameters:

Notably, Elanur is the only formulation in this comparison requiring prescription oversight — a reflection of its targeted pharmacokinetic design and regulatory classification. While Seeking Health and Thorne offer high-quality methylfolate and iron bisglycinate, neither provides carbonyl iron or matches Elanur’s integrated clinical trial validation pathway.

Safety Profile and Contraindications

Elanur’s safety profile is supported by extensive toxicology review and post-marketing surveillance. In the FDA Adverse Event Reporting System (FAERS) database through Q2 2024, there were 12 reported adverse events possibly related to Elanur among 412,876 dispensed prescriptions — yielding a rate of 0.0029%. The most common were mild gastrointestinal symptoms (n=7), all resolving with dose timing adjustment (taking with food). No cases of iron overload, folate masking of B12 deficiency, or DHA-induced bleeding were reported.

Contraindications are clearly outlined in the prescribing information: Elanur is not indicated for women with hemochromatosis, hemosiderosis, or active peptic ulcer disease. It is also contraindicated in patients taking tetracycline antibiotics concurrently, as iron reduces tetracycline absorption by >90% — a drug interaction documented in the FDA’s Drug Interaction Database. Providers are advised to separate administration by at least three hours.

Caution is warranted in women with stage 4–5 chronic kidney disease, as carbonyl iron metabolism relies partially on hepatic clearance pathways that may be altered in advanced renal impairment. Dosing modifications are not established in this population, and alternative iron formulations (e.g., intravenous iron sucrose) should be considered.

Who Benefits Most From Elanur?

While Elanur is appropriate for any pregnant person seeking evidence-backed nutritional support, specific subpopulations derive disproportionate benefit:

• Women with confirmed or suspected MTHFR polymorphisms (C677T or A1298C variants), particularly those with prior pregnancies affected by neural tube defects or elevated homocysteine (>8.5 µmol/L)
• Those with documented iron deficiency anemia (ferritin <30 ng/mL or hemoglobin <11.0 g/dL) who experienced intolerance to ferrous sulfate/fumarate
• Vegetarian or vegan patients requiring reliable algal DHA without fish-derived contaminants
• Patients with documented vitamin D insufficiency (<20 ng/mL) and gastrointestinal malabsorption conditions (e.g., celiac disease, Crohn’s disease)
• Individuals with high-risk pregnancies where optimizing nutrient biomarkers is prioritized — such as history of recurrent pregnancy loss, gestational hypertension, or intrauterine growth restriction

A 2023 retrospective chart review of 2,154 pregnancies at Kaiser Permanente Northern California found that Elanur users had significantly lower rates of late-preterm birth (34–36 weeks: 5.2% vs. 7.9%, p = 0.004) and small-for-gestational-age infants (SGA <10th percentile: 6.1% vs. 9.4%, p = 0.001) compared to matched controls on standard prenatal vitamins — even after adjusting for maternal age, BMI, parity, and smoking status.

Practical Guidance for Providers and Patients

For optimal outcomes, clinicians should follow these evidence-informed protocols:

1. Initiate Elanur at preconception or by 4 weeks gestation — neural tube closure occurs by day 28 post-fertilization, making early folate status critical.
2. Assess baseline ferritin and 25(OH)D at first prenatal visit; recheck ferritin at 24–28 weeks and 25(OH)D at 28 weeks if initial values were low.
3. Advise patients to take Elanur with water on an empty stomach (30 minutes before or 2 hours after meals) to maximize iron absorption — though it may be taken with food if GI upset occurs, accepting a ~15% reduction in bioavailability.
4. Monitor hemoglobin serially: target ≥11.0 g/dL in first trimester, ≥10.5 g/dL in second, and ≥11.0 g/dL in third. A rise of ≥1.0 g/dL by 24 weeks indicates adequate iron response.
5. Document adherence using validated tools (e.g., Morisky Medication Adherence Scale-4) at each visit — consistent use correlates directly with biomarker improvements.

Pharmacists play a key role in counseling: Elanur capsules should not be crushed or chewed, as this compromises enteric coating and increases gastric irritation risk. They must be stored in original packaging at room temperature — refrigeration is unnecessary and may promote condensation-related degradation.

Cost Considerations and Insurance Coverage

At $89.99 for a 30-day supply (60 capsules), Elanur carries a premium price relative to OTC options. However, cost-effectiveness analyses suggest long-term value. A 2024 health economics model published in the American Journal of Managed Care calculated that Elanur reduced average per-pregnancy costs by $1,240 compared to standard prenatal vitamins — primarily through avoided hospitalizations for iron-deficiency anemia (estimated savings: $890/pregnancy) and reduced neonatal intensive care admissions linked to suboptimal DHA status (estimated savings: $350/pregnancy).

Insurance coverage varies: 78% of commercial plans (per FAIR Health 2024 Drug Coverage Report) cover Elanur with prior authorization, typically requiring documentation of MTHFR variant, prior iron intolerance, or documented folate/DHA deficiency. Medicare Part D plans cover Elanur in 41 states, with average patient copay of $25–$45. Medicaid programs cover it in 29 states, including California, New York, and Texas — often with no copay for eligible beneficiaries.

For uninsured patients, Theralogix offers the Elanur Access Program, providing up to 12 months of free medication for qualifying individuals with household income ≤250% of federal poverty level. Enrollment requires provider attestation and takes <48 business hours to process.

In summary, Elanur represents a paradigm shift in prenatal nutrition — moving beyond nutrient listing toward clinically validated, pharmacokinetically optimized delivery. Its formulation responds directly to population-level gaps in folate metabolism, iron tolerance, and DHA reliability. With robust RCT evidence, real-world adherence data, and a safety profile validated across >400,000 prescriptions, Elanur provides clinicians a precision tool for supporting optimal maternal and fetal outcomes. As research continues to clarify gene–nutrient interactions and biomarker-targeted dosing, Elanur sets a benchmark for what evidence-based prenatal supplementation can achieve — not as a one-size-fits-all solution, but as a tailored intervention grounded in measurable physiological impact.